🇪🇸 Spain · EU Public Tender
Medicamentos exclusivos: Omalizumab (XOLAIR), Ranibizumab (LUCENTIS), Everolimus (VOTUBIA), Basiliximab (SIMULEC). 3ª Prórroga P.N.S.P. 21/2019.
🏛️ Servicio Madrileno de Salud, Hospital Universitario La Paz · 📍 Madrid
2.1M €
Estimated value
—
Deadline
| Contract type | Supplies |
| CPV | 33600000 |
| Awarded to | Novartis Farmacéutica, S.A. |
Full tender details, bidder list, market context and related contracts available below.
Data sourced from TED — the Official Journal of the EU.